Trending News Today: Study Shows Taltz Superior to Humira in Active Psoriatic Arthritis

Top news of the day across the health care landscape.

Eli Lilly’s psoriatic arthritis drug Taltz proved to be more effective than AbbVie’s Humira in a late-stage clinical trial, Reuters reported. According to the article, the trial tested Taltz and the standard-of-care Humira in patients with active psoriatic arthritis. The study showed that Taltz was as effective as Humira in improving symptoms of psoriatic arthritis but was superior to Humira in clearing skin completely in a greater number of patients and achieving both results simultaneously, Reuters reported.

A recent poll found approximately 3 in 10 Americans delayed seeking medical treatment within the past year due to medical costs, according to The Hill. The Gallup poll showed that 29% of respondents put off treatment because of cost and approximately 19% said they delayed treatment for serious or somewhat serious conditions, the article noted. An average of 30% of respondents said they had put off treatment each year because of costs since 2005, up from 24% in the 4 years before that, according to the poll.

US Surgeon General Jerome Adams warned about the risks of e-cigarette use in children and teens in an advisory on Tuesday, the Associated Press reported. The surgeon general’s advisory said parents, health professionals, and government officials must take “aggressive steps” to keep minors from using e-cigarettes. Separate survey results released Monday showed twice as many high school students used e-cigarettes this year compared with last year, the article noted.